Biotechnology

Azitra

Azitra released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6713 (forecast USD -0.775)

Azitra released FY2025 9 Months earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -3.4047

Azitra released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1818 (forecast USD -1.3986)

Azitra released FY2025 Semi-Annual earnings on August 11 (EST), actual revenue USD 0, actual EPS USD -0.4043

Azitra Inc. Annual General Meeting Approves Increase in Common Stock Authorization

Azitra Inc. Reports Safety Data for ATR12-351 Phase 1b Trial

Azitra, Inc. to Present Latest Advances in Therapies

Azitra Inc. to Present ATR-04 Clinical Trial Results at ASCO Annual Meeting

Azitra released FY2025 Q1 earnings on May 13 (EST) with actual revenue of USD 0 and EPS of USD -1.5514

Azitra Announces Q1 Financials and Business Updates

Azitra Announces ATR04-484 Phase 1/2 Clinical Trial

Azitra released FY2024 annual earnings on February 24 (EST), actual revenue 7.5 K USD (forecast 8 K USD), actual EPS -2.3695 USD (forecast -2.05 USD)

Azitra released FY2024 Q4 earnings on February 24 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.0822 (forecast USD -2.0646)

Azitra released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1421 (forecast USD -2.331)

Azitra released FY2024 9-month earnings on November 12 (EST), actual revenue USD 7.5K, actual EPS USD -7.2349

Azitra Administers First Dose in ATR-12 Phase 1B Trial for Netherton Syndrome

Azitra released FY2024 Q2 earnings on August 12 (EST), actual revenue USD 7.5 K (forecast USD 0), actual EPS USD -18.2566 (forecast USD -13.1202)

Azitra released FY2024 Semi-Annual earnings on August 12 (EST), actual revenue USD 7.5K, actual EPS USD -6.8159

Azitra Announces Public Offering of Common Stock and Warrants Priced at $100 Million

Azitra submits a mixed shelf offering application-SEC filing for up to $50 million

AMC Robotics

Radiopharm Theranostics

Artiva Biotherapeutics

Netclass Tech

3 E Network Tech

Quipt Home Medical

Kaixin

Ascent Solar Tech

Click Holdings/BVI

Climb Bio

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap